They reported higher expression of inhibitory receptors in BM T-cells of AML patients at diagnosis compared to healthy controls and the co-expression of different inhibitory molecules in relapsed patients; moreover, they observed the expression of immune-checkpoint ligands on the blasts of patients with adverse cytogenetics and p53 mutations [106]. The gene discussed is TP53; the disease is acute myeloid leukemia.